Get the Stockscreener App
0.8225
2.98%
-0.0253
After Hours:
.86
0.0375
+4.56%
Carisma Therapeutics Inc stock is traded at $0.8225, with a volume of 206.15K.
It is down -2.98% in the last 24 hours and down -16.07% over the past month.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
See More
Previous Close:
$0.8478
Open:
$0.8478
24h Volume:
206.15K
Relative Volume:
1.44
Market Cap:
$34.34M
Revenue:
$14.92M
Net Income/Loss:
$-86.88M
P/E Ratio:
-0.2679
EPS:
-3.0699
Net Cash Flow:
$-82.31M
1W Performance:
-6.87%
1M Performance:
-16.07%
6M Performance:
-41.67%
1Y Performance:
-68.12%
1-Day Range:
$0.82
$0.8593
1-Week Range:
$0.82
$0.91
52-Week Range:
$0.80
$3.16
Carisma Therapeutics Inc Stock (CARM) Company Profile
Name
Carisma Therapeutics Inc
Sector
Industry
Phone
(267) 491-6422
Address
3675 MARKET STREET, PHILADELPHIA
Compare CARM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CARM | 0.8225 | 34.34M | 14.92M | -86.88M | -82.31M | -3.0699 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-06-23 | Initiated | Evercore ISI | Outperform |
| May-31-23 | Upgrade | Jefferies | Hold → Buy |
| May-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
Carisma Therapeutics Inc Stock (CARM) Latest News
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CA - GuruFocus.com
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 - PR Newswire
Carisma Therapeutics Reports Q3 2024 Results, Advances Clinical Programs - MSN
Carisma Therapeutics stock a buy at D. Boral Capital, HER2 & platform value in focus - Investing.com India
Carisma Therapeutics and Moderna Unveil Promising Pre-Clinical Data for Anti-GPC3 CAR-M Therapy - MSN
Carisma Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Carisma reports progress in liver cancer therapy development - Investing.com India
Carisma reports progress in liver cancer therapy development By Investing.com - Investing.com Australia
Carisma Therapeutics reports data from its CAR-M therapy - TipRanks
Carisma Therapeutics Inc. Unveils Promising Pre-Clinical Data on Anti-Gpc3 in Vivo Car-M Therapy for Hepatocellular Carcinoma - Marketscreener.com
Carisma Therapeutics reports Q3 EPS (31c), consensus (26c) - TipRanks
Carisma Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CARISMA Therapeutics Inc Reports Q3 2024 Revenue of $3.39M and G - GuruFocus.com
Carisma Therapeutics Welcomes Sohanya Cheng to Board of Directors - MSN
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 - Citizentribune
Carisma to present new data on CAR-M therapy for hepatocellular carcinoma - TipRanks
Carisma Therapeutics (NASDAQ:CARM) Upgraded at EF Hutton Acquisition Co. I - Defense World
Carisma shares climb on EF Hutton Buy rating - Investing.com India
Carisma Therapeutics Appoints Sohanya Cheng to Board of Directors - citybiz
Carisma Therapeutics names Sohanya Cheng to board - Investing.com India
Carisma Therapeutics Announces Changes to its Board of Directors - Quantisnow
Carisma Therapeutics Reports Second Quarter 2024 Financial Resul - GuruFocus.com
Carisma Therapeutics faces Nasdaq delisting over market value By Investing.com - Investing.com Australia
Carisma Therapeutics faces Nasdaq delisting over market value - Investing.com
Carisma Therapeutics to Showcase Cutting-Edge Cancer Research at SITC 2024 - MSN
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 - Yahoo Finance
Carly Rae Jepsen is engaged! Canadian singer shares happy news on social media: 'Very engaged over here' - Yahoo Canada Shine On
Carly Rae Jepsen Flaunts Blue Engagement Ring with Grammy Winning Fiancé - 2paragraphs Buzz
CRDF (Cardiff Oncology Inc) has impressive results - US Post News
Berkley W R Corp Sells 451,295 Shares of Cartica Acquisition Corp (NASDAQ:CITE) - MarketBeat
Carly Rae Jepsen is a fiancée! Singer announces engagement to Grammy-winning producer - USA TODAY
Carly Rae Jepsen Engaged to Producer Cole MGN: See Her RingE! Online - E! NEWS
'Very engaged over here': Singer Carly Rae Jepsen announces her engagement to music producer Cole M.G.N. - 9Honey Celebrity
Investing in Aclaris Therapeutics Inc (ACRS) Is Getting More Attractive - Knox Daily
Surprise! Carly Rae Jepsen Is Engaged!!! - PerezHilton.com
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now - Benzinga
Carly Rae Jepsen announces engagement to boyfriend Cole MGN after two years of dating - Daily Mail
Carly Rae Jepsen Proclaims Herself ‘Very Engaged Over Here’ in Photoshoot Showing Off Ring From Fiancé Cole M.G.N. - Billboard
Carly Rae Jepsen Engaged to Producer Cole M.G.N. - AceShowbiz Media
Carly Rae Jepsen & Boyfriend Cole M.G.N. Are Engaged! - Just Jared
Cole M.G.N. Entertainment News, Photos, and Videos - Just Jared
A closer look at Cara Therapeutics Inc (CARA) is warranted - US Post News
Hancock Whitney Corp Has $737,000 Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Where Are They Now? Carisma Therapeutics - Life Science Leader Magazine
Gabelli Funds LLC Has $120.74 Million Stake in Crane (NYSE:CR) - MarketBeat
Corbus Pharmaceuticals (NASDAQ:CRBP) PT Lowered to $40.00 at B. Riley - Defense World
Cosmic CRF shares hit 5% upper circuit on Rs 127-crore order win; details - Business Standard
Carisma Therapeutics Inc Stock (CARM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):